This article first appeared on GuruFocus.
AbbVie (NYSE:ABBV), the global immunology and pharmaceutical company, said Qulipta achieved the main goal of a Phase 3 trial targeting menstrual migraine. Shares traded at $252.25 Thursday morning, up approximately 0.4%.
Warning! GuruFocus has detected 5 Warning Signs with INTC.
Is ABBV fairly valued? Test your thesis with our free DCF calculator.
The trial tested a sharper, more targeted treatment schedule. Patients received atogepant for seven straight days, starting three days before menstruation, across three cycles. Qulipta reduced perimenstrual migraine days by 0.8 versus placebo while also improving headache burden, rescue-medication use, disability and cognitive symptoms.
The commercial prize could be meaningful. Qulipta delivered $350 million in second-quarter revenue, rising 30.9% and accounting for roughly 10.8% of AbbVie's $3.23 billion neuroscience portfolio. The picture adds a valuation warning: the $252.25 share price stands 14.55% above the $220.20 GF Value estimate. Intermittent dosing could widen Qulipta's market, but detailed safety results, regulatory approval and insurer coverage still separate positive data from new revenue.